Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6042869 | 0.84 | ALDH1A1 (0.45) | OPRK1OPRD1OPRM1CNR2ALDH1A1 | |
| SCHEMBL4615941 | 0.81 | OPRK1 (0.51) | OPRK1OPRD1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7076745 | 0.80 | OPRL1 (0.42) | OPRL1OPRK1MCHR1DRD4ALDH1A1 | |
| SCHEMBL6950570 | 0.78 | SLC6A2 (0.50) | OPRL1 | |
| SCHEMBL27522709 | 0.75 | REN (0.50) | — | |
| SCHEMBL6094891 | 0.74 | OPRK1 (0.40) | OPRK1OPRD1OPRM1SMN1; SMN2 | |
| SCHEMBL6094894 | 0.74 | OPRK1 (0.40) | OPRK1OPRD1OPRM1SMN1; SMN2 | |
| SCHEMBL8306369 | 0.74 | OPRK1 (0.40) | OPRK1OPRD1OPRM1SMN1; SMN2 | |
| SCHEMBL6042667 | 0.73 | MCHR1 (0.40) | OPRL1MCHR1CCR1DRD4 | |
| SCHEMBL4941602 | 0.73 | OPRK1 (0.49) | OPRL1OPRK1OPRD1OPRM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | OPRL1 1154/4885OPRK1 2316/4885OPRD1 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.